Compare Kohl's Corporation (KSS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Repligen Corporation Common Stock — how do they compare? Kohl's Corporation trades at $21.11 (market cap $2.39B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 4.7× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.37% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Repligen Corporation Common Stock for 0 Days on average.
| KSS | RGEN | |
|---|---|---|
Market Cap | $2.39B | $11.14B |
Volume | 4,591,325 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $194.57 |
52-Week Low | $11.72 | $102.87 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.99B | $11.02B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $21.15, down slightly by 0.09% on the day, with the stock showing bullish technical signals from moving averages. The company has beaten earnings expectations for three consecutive quarters, including a significant Q2 2026 beat of $1.28 EPS versus $0.58 expected. Despite declining revenues, Kohl's maintains attractive valuation metrics with a P/E of 9.06 and P/S of 0.16, while recent management changes and operational improvements provide potential catalysts.
The investment case centers on deep value metrics and operational turnaround potential, though persistent revenue declines and competitive pressures remain key risks. Analyst sentiment is mixed with 30% buy ratings but a consensus price target of $15.50 below current levels, suggesting cautious optimism about the company's ability to stabilize sales and improve profitability in a challenging retail environment.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
